Neuromodulation of the sacral nerves has been found to be an effective therapy for a variety of lower urinary tract dysfunctions. The reported success rate for the period of trial stimulation (peripheral nerve evaluation test) prior to permanent implantation of a sacral nerve stimulator is variable, but generally reported to be in the region of 30–50%. We present here the results of the peripheral nerve evaluation test in 38 patients with urinary retention. 34 of the 38 had been found to have an abnormality of their striated urethral sphincter on electromyography using a concentric needle electrode, i.e., they had the disorder which was described by Fowler and coworkers in 1988. The overall success rate in this group was 68%. We believe that our relatively high success rate is due to sacral neuromodulation working via a mechanism which involves the urethral sphincter, an abnormality which had been demonstrated in 89% of these patients. Twelve of the patients subsequently underwent permanent implantation of a sacral nerve stimulator, and all of them have experienced a return of voiding. However, in 2 patients, there is a persisting need for self–catherization. There is, however, a high reoperation rate.

Keywords:
Sacral neuromodulation, Urinary retention, Fowler’s syndrome
1.
Dijkema HE, Weil EHJ, Mijs PT, Janknegt RA: Neuromodulation of sacral nerves for incontinence and voiding dysfunctions. Eur Urol 1993;24:72–76.
2.
Weil EH, Ruiz–Cerda JL, Eerdmanns PH, Janknegt RA, van Kerrebroeck PEV: Clinical results of sacral neuromodulation for chronic voiding dysfunction using unilateral sacral foramen electrodes. World J Urol 1998;16: 313–321.
3.
Bosch JL, Groen J: Neuromodulation: Urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperreflexia. Behav Brain Res 1998; 92:141–150.
4.
Shaker HS, Hassouna M: Sacral nerve root neuromodulation: An effective treatment for refractory urge incontinence. J Urol 1998;159: 1516–1519.
5.
Shaker HS, Hassouna M: Sacral root neuromodulation in idiopathic nonobstructive chronic urinary retention. J Urol 1998;159: 1476–1478.
6.
Grunewald V, Hofner K, Thon WF, Kuczyk MA, Jonas U: Sacral electrical neuromodulation as an alternative treatment option for lower urinary tract dysfunction. Restor Neurol Neurosci 1999;14:189–193.
7.
Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PEV: Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol 1999;162:352–357.
8.
Fowler CJ, Christmas TJ, Chapple CR, et al: Abnormal electromyographic activity of the urethral sphincter, voiding dysfunction, and polycystic ovaries: A new syndrome? BMJ 1988;297:1436–1438.
9.
Swinn MJ, Fowler CJ: The clinical features of non–psychogenic urinary retention in young women (Fowler’s syndrome). Neurourol Urodyn 1998;17:304–305.
10.
Noble JG, Dixon PJ, Rickards D, Fowler CJ: Urethral sphincter volumes in women with obstructed voiding and abnormal sphincter electromyographic activity. Br J Urol 1995;76: 741–746.
11.
Koldewijn EL, Rosier PFWM, Meuleman EJH, Koster AM, Debruyne FMJ, van Kerrebroeck PEV: Predictors of success with neuromodulation in lower urinary tract dysfunction: Results of trial stimulation in 100 patients. J Urol 1994;152:2071–2075.
12.
Grunewald V, Hofner K, Kuczyk M, Jonas U: Sacral neuromodulation: Long–term results of 55 patients with incontinence and voiding dysfunction. Eur Urol 1999;35(suppl 2):16.
13.
Thon WF, Baskin LS, Jonas U, Tanagho EA, Schmidt RA: Neuromodulation of voiding dysfunction and pelvic pain. World J Urol 1991;9:138–141.
14.
Swinn MJ, Kitchen ND, Schott G, Oliver SE, Fowler CJ: Leg pain following sacral neuromodulation. Br J Urol 1999;84:150–151.
15.
McGuire EJ: Experimental observations on the integration of bladder and urethral function. Trans Am Assoc Genito–urin Surg 1977;68: 38–42.
16.
Fowler CJ, Swinn MJ: The long latency of anal sphincter contraction on S3 stimulation shows the reflex is afferent–mediated. Neurourol Urodyn 1998;17:355–356.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.